CMCarine W. Maurer

Carine W. Maurer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carine W. Maurer has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From evidence to practice: Expert consensus for sleep dysfunction in Parkinson disease

    by Carine W. Maurer, Delaram Safarpour, Joyce K. Lee-Iannotti, Lana M. Chahine, Jeanne Feuerstein, Amy W. Amara, Eleni Okeanis Vaou, Aleksandar Videnovic, Miranda M. Lim, David Shprecher, et al.

  • Open Access

    True vignettes: interesting, illustrative examples of behavioral abnormalities in people with Parkinson's disease

    by Joseph H. Friedman, Umer Akbar, Blake Beehler, Kelvin L. Chou, Leslie J. Cloud, Andres Deik, Rebecca Gilbert, Stephen N. Gomperts, John L. Goudreau, Steven A. Gunzler, et al.

    Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurobehavioral disorders in which behavioral abnormalities are common but often not recognized. To bring to life the actual descriptions rendered by our patients of their unusual experiences. Members of the Parkinson Study Group were asked to provide illustrative examples of particularly memorable abnormal behaviors that their own PD patients or family members reported. These recollections were deidentified and sorted into categories. These disorders include the classically described syndromes of Capgras, Cotard, Diogenes, Ekbom, Othello as well as overlap parasomnias, and impulse control disorders. Patients with PD often have had unusual experiences that they may not share without inquiries by their healthcare providers, fearful of how they will be perceived. Sensitive inquiries are required to reveal these problems. We believe that reading about real experiences will help sensitize the reader.

  • ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease

    by Aleksandar Videnovic, Christopher S. Coffey, Elizabeth B. Klerman, Merit Cudkowicz, Hyun Joo Cho, Amy Amara, Karen Marder, Phyllis Zee, Christina Desir, Holly Ernst, et al.

    Background: Light therapy (LT) in Parkinson's disease improves sleep. Specific LT parameters require further study, including optimal frequency. Objectives: We aimed to determine if once‐ or twice‐daily bright white light therapy (BWLT) improves sleep. Secondary aims compared once‐weekly BWLT to twice‐daily dim red light therapy (DRLT) as controls, estimated effects on fatigue, and adherence. Methods: A 16‐week, randomized, phase 2, sham‐controlled, dose‐selection trial to select the superior BWLT frequency based on change in Parkinson's Disease Sleep Scale‐2 (PDSS‐2), participant burden, and safety. Participants were randomized to 8 weeks of twice‐daily BWLT, once‐daily BWLT, once‐weekly BWLT, or twice‐daily DRLT. An improvement of ≥1.7 points in 8‐week change of PDSS‐2 by daily BWLT relative to either control warranted advancing to a phase 3 trial. Results: A total of 150 participants were randomized (mean [SD], 67 [8.6] years; 57 [38%] female; PDSS‐2 17.1 [6.7]). Mean 8‐week change from baseline in PDSS‐2 score improved (twice‐daily BWLT −2.6 [95% CI: −4.4, −0.7]; once‐daily BWLT ‐1.5 [−3.3, 0.3]; once‐weekly BWLT −0.4 [−2.2, 1.4]; twice‐daily DRLT −1.8 [−3.6, 0.1]) but did not meet criteria for advancing. Mean 8‐week change from baseline in Parkinson's Disease Fatigue Scale (PFS‐16) score improved (twice‐daily BWLT −6.4 [−9.8, −3.0]; once‐daily BWLT −2.2 [−5.5, 1.1]; once‐weekly BWLT −0.5 [−3.9, 2.8]; and twice‐daily DRLT −3.8 [−7.3, −0.4]). Mean adherence to LT was 63%–86%. Conclusions: ENLITE‐PD did not meet the criteria for advancing daily LT to a phase 3 trial. LT was safe and well‐tolerated with good adherence. Once‐weekly BWLT was a non‐inferior control compared with twice‐daily DRLT. © 2025 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.


  • Recognising and managing functional neurological disorder in the acute healthcare setting

    by Andre Galenchik-Chan, Thomas Ren, David Cohen, Carine W Maurer

    Functional neurological disorder (FND) is a complex and heterogenous condition characterised by abnormal neurological symptoms that are linked to structural and functional alterations in widely distributed brain networks. For many patients with FND, the emergency department (ED) is the first point of contact with the healthcare system. This review seeks to provide up-to-date FND diagnostic criteria to ED providers, with a focus on common FND subtypes. Furthermore, we summarise the appropriate management course for these patients. Proper recognition and management of FND at the time of initial presentation in the acute care setting has the potential to improve patient prognosis and reduce overall costs to the healthcare system.


  • Open Access

    Long-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection

    by Rachel Pakan, Roham Hadidchi, Yousef Al-Ani, Hannah Piskun, Katie S. Duong, Sonya Henry, Stephen Wang, Carine W. Maurer, Tim Q. Duong

    Background/Objectives: Although COVID-19 has been linked to worse outcomes in patients with neurological disorders, its impact on those with essential tremor (ET) remains unclear. To investigate clinical outcomes of ET patients with and without COVID-19 three and a half years post-pandemic. Methods: 1074 ET patients were evaluated in this retrospective study in the Montefiore Health System from January 2016 to July 2023. Comparisons between ET patients with and without a positive SARS-CoV-2 polymerase chain reaction test were made. Outcomes included post-index date major adverse cardiovascular events (MACEs), new-onset sleep disturbances, fatigue, dyspnea, first-time fall, new-onset anxiety, new-onset depression, headache, new-onset imbalance, new-onset mild cognitive impairment, and all-cause mortality, adjusted hazard ratios (aHR) adjusting for covariates were calculated. Results: ET patients with COVID-19 had higher prevalence of pre-existing type-2 diabetes, depression, and anxiety compared to ET patients without COVID-19. COVID-19 was significantly associated with higher risk of MACEs, (aHR = 2.39 [1.49, 3.82]), new-onset sleep disturbance, (aHR = 2.12 [1.44, 3.13]), fatigue, (aHR = 1.83 [1.27, 2.65]), dyspnea, (aHR = 1.98 [1.40, 2.80]), first-time fall, (aHR = 4.76 [2.24, 10.14]), new-onset anxiety, (aHR = 3.66 [2.02, 6.64]), and new-onset depression, (aHR = 2.38 [1.20, 4.70]). COVID-19 was not associated with all-cause mortality. Conclusions: In patients with ET, COVID-19 significantly increases the risk of several long-term adverse health outcomes, but not mortality.


  • A Pilot Group Cognitive Behavioral Therapy Telehealth Intervention for Functional Movement Disorder

    by Vera N. Kulikov, Dodie A. Gillett, Carine W. Maurer


  • Essential tremor accentuates the pattern of tremor-band coherence between upper limb muscles

    by Daniel B. Free, Ian Syndergaard, Adam C. Pigg, Silvia Muceli, Johanna Thompson-Westra, Karin Mente, Carine W. Maurer, Dietrich Haubenberger, Mark Hallett, Dario Farina, et al.

    We characterized the relationships in tremor-band activity between the 15 major superficial upper limb muscles of persons with essential tremor by quantifying the proportion of shared activity (coherence) in the tremor band and by characterizing phase differences between these muscles during various tasks. From our observations, we conclude that tremor enhances the coherence between muscle pairs throughout the upper limb in a pattern that reflects functional relationship between them.


  • Tic Disorders, Anti‐Tic Medications, and Risk of Atopy

    by Mathew Hakimi, Sandra Skinner, Carine W. Maurer

    Objective: To clarify patterns of comorbid atopic disorders in children with tic disorders compared to controls, and to evaluate whether medications commonly used for treatment of tics and attention deficit hyperactivity disorder (ADHD) are associated with differing risks of atopy.Background: Inflammatory mechanisms are increasingly recognized as playing a role in a range of neuropsychiatric disorders. The association between tic disorders, ADHD, obsessive–compulsive disorder (OCD) and atopic disorders is uncertain.Methods: We performed a retrospective cohort study using the global electronic health records database TriNetX. Using odds ratios, we compared the risk of atopy in children with tic disorder (n = 4508), ADHD (n = 83,569), and/or OCD (n = 1555) to controls (n = 758 290). To analyze the risk of developing atopy with use of different medications commonly prescribed to treat tics and ADHD, we performed a separate analysis including children with tic disorder, ADHD, and/or OCD who had initiated treatment with one of these medications. Binary logistic regression controlling for age and sex was used to calculate odds ratios.Results: Children with tic disorder, ADHD, or OCD were more likely than controls to have comorbid atopy. Children who had taken clonidine, guanfacine, methylphenidate, or dexmethylphenidate were more likely to develop an atopic disorder than controls.Conclusions: Our study suggests a link between atopic disorders and tic disorders, ADHD, and OCD. Although the underlying mechanism for this association remains unclear, medication use may play a role.


  • Top Cited Papers
    Open Access

    Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda

    by David L. Perez, Timothy R. Nicholson, Ali A. Asadi-Pooya, Indrit Bègue, Matthew Butler, Alan J. Carson, Anthony S. David, Quinton Deeley, Ibai Diez, Mark J. Edwards, et al.


  • Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade

    by K LaFaver, A E Lang, J Stone, F Morgante, M Edwards, S Lidstone, C W Maurer, M Hallett, A K Dwivedi, A J Espay

    Background and purpose: There is large variability in the diagnostic approach and clinical management in functional movement disorders (FMD). This study aimed to examine whether opinions and clinical practices related to FMD have changed over the past decade.Methods: Adapted from a 2008 version, we repeated the survey to members of the International Parkinson and Movement Disorder Society (MDS).Results: In all, 864/7689 responses (denominator includes non‐neurologists) were received from 92 countries. Respondents were more often male (55%), younger than 45 (65%) and from academic practices (85%). Although the likelihood of ordering neurological investigations prior to delivering a diagnosis of FMD was nearly as high as in 2008 (47% vs. 51%), the percentage of respondents communicating the diagnosis without requesting additional tests increased (27% vs. 19%;P = 0.003), with most envisioning their role as providing a diagnosis and coordinating management (57% vs. 40%;P < 0.001). Compared to patients with other disorders, 64% of respondents were more concerned about missing a diagnosis of another neurological disorder. Avoiding iatrogenic harm (58%) and educating patients about the diagnosis (53%) were again rated as the most effective therapeutic options. Frequent treatment barriers included lack of physician knowledge and training (32%), lack of treatment guidelines (39%), limited availability of referral services (48%) and cultural beliefs about psychological illnesses (50%). The preferred term for communication favored ‘functional’ over ‘psychogenic’ (P < 0.001).Conclusions: Attitudes and management of FMDs have changed over the past decade. Important gaps remain in access to treatment and in the education of neurologists about the inclusionary approach to FMD diagnosis.